Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05338775 · ClinicalTrials.gov registry record · Phase 1
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Relapsed Refractory Multiple Myeloma, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
- 19
- Study locations
NCT05338775 is a Phase 1 study of Relapsed Refractory Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 74 participants, below the 180-participant average among 4 other Relapsed Refractory Multiple Myeloma trials with a reported enrollment target (59% lower). The trial reports 19 study locations across 5 states.
The verdict
NCT05338775, a Phase 1 study of Relapsed Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Talquetamab
- DRUG PD-1 Inhibitor
Study Locations (19)
Other
- CHU de Montpellier Hopital Saint Eloi - Montpellier
- CHU de Nantes hotel Dieu - Nantes
- CHU Poitiers - Hopital la Miletrie - Poitiers
- Institut Universitaire du Cancer Toulouse Oncopole - Toulouse
- Universitatsklinikum Carl Gustav Carus Dresden - Dresden
- Universitaetsklinikum Hamburg Eppendorf - Hamburg
- Universitaetsklinikum Heidelberg - Heidelberg
- Universitatsklinikum Wurzburg - Würzburg
- Hosp. Univ. Germans Trias I Pujol - Badalona
- Hosp Univ Fund Jimenez Diaz - Madrid
- Clinica Univ. de Navarra - Pamplona
- Hosp Clinico Univ de Salamanca - Salamanca
New York
- The Blavatnik Family Chelsea Medical Center at Mount Sinai - New York
- Icahn School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Sarah Cannon Research Institute - Nashville
- Vanderbilt Ingram Cancer Center - Nashville
Colorado
- Colorado Blood Cancer Institute - Denver
North Carolina
- Wake Forest Baptist Medical Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2027-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05338775
The ClinicalTrials.gov registry entry for NCT05338775 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 4 other Relapsed Refractory Multiple Myeloma trials with a reported enrollment target (59% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed Refractory Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Teclistamab is the first listed.
NCT05338775 reports 19 study locations spanning 5 distinct geographic areas - top geographies include Other, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05338775 about?
NCT05338775 is a clinical study titled "A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma". The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
What is the current status of trial NCT05338775?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2022-05-25. Estimated completion is 2027-05-03.
What conditions does trial NCT05338775 study?
This clinical trial studies the following conditions: Relapsed Refractory Multiple Myeloma.
What interventions are being tested in trial NCT05338775?
The interventions under investigation include: Teclistamab (DRUG), Talquetamab (DRUG), PD-1 Inhibitor (DRUG).
Who is sponsoring clinical trial NCT05338775?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05338775 being conducted?
This trial has 19 study locations across Colorado, New York, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Myeloma-Developing Regimens Using Genomics (MyDRUG)
COMPLETED · Phase 1
-
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RECRUITING · Phase 3
-
ELISA in Relapsed/Refractory MM
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.